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ABSTRACT
Breast carcinoma is the most frequently diagnosed cancer among women and causes
over 400,000 deaths each year worldwide. Current treatments such as chemotherapy
are not selective for cancerous tissues but are destructive to normal tissues as well.
This causes a range of side effects including pain, nausea, hair loss, weakness, and
more. Inactivation of p53 is a very common mutation within human cancer cells. The
ability to activate the p53 pathway, which protects cells from tumor formation, is lost
in 50% of cancers. Due to the prevalence of this mutation, p53 is a uniquely valuable
target for applied research. Alpha mangostin is an extract from a southeast Asian fruit,
Garcinia mangostana. It has potential to be an effective p53 activator in which the
small molecule disrupts the binding of p53 to MDM2, a negative regulator, inducing
the p53 cascade, which results in cell cycle arrest for low level stressors. This protects
the cells from paclitaxel, a chemotherapy agent that only kills actively dividing cells.
Here, we hypothesized that alpha mangostin protects wild-type, but not p53 (-/), MCF10A breast cancer cells from the chemotherapeutic agent paclitaxel. When
MCF10A wild-type cells were cotreated with alpha mangostin and paclitaxel, alpha
mangostin exhibited a protective effect on the cells. However, when MCF10A P53
knockout cells were treated with alpha mangostin, cell viability decreased, indicating a
loss of protective effect in the p53 distressed cancer cells. These results further support
treatments that target chemoprotection via p53 pathway in wild-type cells, and the use
of alpha mangostin warrants further study.
LITERATURE REVIEW
Breast carcinoma and treatments
The development of cancer is a multistep process that involves complex interactions
between host and tumor tissue. The process involves oncogene activation as well as
immunosuppression, leading to uncontrolled cell growth despite damaged DNA (Wang
2010). Genome instability contributes to cancer development due to mutations in DNA
damage response pathways, which are mediated through the tumor suppressor p53
(Reinhardt & Schumacher, 2012).
Breast carcinoma is the most frequently diagnosed cancer among women and causes
over 400,000 deaths yearly worldwide (Walerych, Napoli, Collavin, & Del Sal,
2012). Metastasis accounts for a large majority of the deaths that result from breast
cancer, mostly to lymph nodes, lungs, and bones. The complexity of cancer leads to
difficulties in treatment. Many of these difficulties are due to the nonselective nature
of the treatment, which cause cell toxicity in noncancerous cells. Treatment plans are
dependent on the stage and characteristics of the cancer as well as the age, menopausal
status, and risk benefit analysis associated with each option. Based on a study in 2017,
stage I and II patients most often receive breast conserving surgery. Stage III patients
most often receive a mastectomy, radiation therapy, as well as chemotherapy with a
five-year survival rate of 72%. Stage IV patients most often receive radiation therapy
and or chemotherapy with a five-year survival rate of about 22% (American Cancer
Society, 2017).
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In order to delay the progression of breast cancer and increase the longevity of patients,
less toxic yet effective chemotherapeutic agents are needed to limit the debilitating
side effects while also improving outcomes (Shibata et al., 2011). These side effects
include pain, lymphedema, musculoskeletal symptoms, bone loss and osteoporosis,
heart problems, new cancers, blood clots, infertility, and loss of memory and cognitive
function. (American Cancer Society, 2017).
Currently, conventional treatments such as radiation, chemotherapy, and surgery have
not been entirely effective against the high incidence and low survival rates of breast
cancer due to its complex nature (Moongkarndi et al., 2004). Research has established
that combinations of drugs are more effective than one drug alone for the treatment of
early-stage breast cancer. An example of such treatment is Trastuzumab, a monoclonal
antibody that directly targets the human epidermal growth factor 2 (HER2) protein.

Figure 1. Various outcomes of the p53 pathway. Different causes, such as those of mild physiological stress or severe
stress, interrupt the mdm2 and p53 binding and result in various outcomes such as DNA repair, growth arrest, apoptosis,
and more (Vogelstein, Hughes, Kimmel, & Cancer, 2013).

When combined with chemotherapy, this treatment was found to reduce the risk
of recurrence by 52% and death by 33% for patients who overproduce the growth
promoting protein HER2/neu (American Cancer Society, 2017). This leads the
scientific community to search for other potential therapeutic approaches including
drug combinations to treating this malignancy and many other cancers that continue to
evade conventional treatments.
P53 gene and cascade
The main function of p53 is to promote genetic stability and prevent the formation of
tumors. When a cell is under stress, it induces cell death through apoptosis for severe
stress or cell arrest and subsequent DNA repair for mild stress in order to prevent
malignant growth. Under normal conditions, p53 levels are low and the binding to
mouse double minute 2 homolog (MDM2) targets it to the proteasome for rapid
degradation and inhibition of its transcriptional activity (Burgess et al., 2016).
Published by Digital Commons @ Olivet, 2019
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When stress occurs, binding to the regulatory protein MDM2 is disrupted due to P53
phosphorylation, which leads to p53 accumulation and subsequent transcription of
numerous genes, including the gene that encodes the cyclin-dependent kinase inhibitor
(CKI) protein p21. P21 binds and inactivates G1/S-Cdk complexes, arresting the cell
in G1 for DNA repair.

Figure 2. The p53 cascade. This figure is a simple representation of a cell’s response to stress that result in DNA damage. The first step is phosphorylation of p53 to affect its binding to mdm2. This process also includes a key player in
the process, p21, which is a Cdk inhibitor. The end result is an inactivation of the G1.S-Cdk and D-Cdk complex with
p21. (Vogelstein, Hughes, Kimmel, & Cancer, 2013).

P53 mutation and treatments
Inactivation of p53 is a very common feature of human cancer cells (Lane, Cheok, &
Lain, 2010). About 50% of adult cancer has p53 inactivated (by mutation or deletion),
while the other 50% has suppressed wild-type p53 function (Choong, Yang, Lee, &
Lane, 2009). On average, p53 is mutated in 20% of tumors in breast cancer. Though
the frequency of mutation is lower in breast cancer cells, p53 inactivation has been
seen in some breast cancers without a mutation. The pathway has been shown to be
affected by alterations in upstream regulatory proteins and downstream p53-induced
256https://digitalcommons.olivet.edu/elaia/vol2/iss1/16
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proteins (Gasco, Shami, & Crook, 2002). In breast cancer, this mutation is associated
with a more aggressive disease and worse overall survival according to several studies
(Gasco et al., 2002).
The ability to activate the p53 pathway that protects cells from tumor formation is lost
in cells with p53 mutations. Most of these mutations occur as a result of a substitution
of single amino acids in the central region of the p53 protein, which causes many
variants (Walerych et al., 2012). Indeed, rapid malignant cell growth, which leads
to many different cancer types, often involves a defective p53 gene, which is the
transcriptional activator that works to suppress tumors in normal tissues (Muller &
Vousden, 2014). In breast cancer, mutant p53 is involved in many processes associated
with cancer development such as early tumorigenesis, tumor growth and development,
and metastasis (Walerych et al., 2012). In clinical practice, molecular pathological
analysis of the tumors of the structure and expression and constituents of the p53
pathway is likely to have value in diagnosis, in prognostic assessment and, ultimately,
in treatment of breast cancer (Gasco et al., 2002).
Chemotherapy and mechanism of chemoprotection
Chemotherapy induces many adverse effects in patients because of normal cell
toxicity, resulting at least in part from p53 activation and apoptosis induction in normal
proliferating cells/tissues such as bone marrow, lymphoid organs, hair follicles, and
epithelium lining of the small intestine (Wang & Sun, 2010). An important aspect of
chemotherapy is that it kills actively dividing cells. In particular, paclitaxel inhibits
microtubule function, which kills cells as they enter mitosis (Blagosklonny, 2002).
Microtubules are essential to the process of mitosis, as they separate chromosomes
to opposite sides of the cell during anaphase. When paclitaxel inhibits the ability for
the chromosomes to be separated during the division process, the cell is inactivated
and eventually is killed. Therefore, wild-type cells treated with the p53 activator are
arrested in G1 and do not enter into mitosis; therefore, the chemotherapy selectively
kills p53-deficient cancer cells. This mechanism can be experimentally controlled with
the use of p53 activators to arrest p53 wild-type cells and protect against the harmful
effects of chemotherapeutic agents on noncancerous cells.
P53 activator current research
Due to the prevalence of this mutation, p53 is a uniquely valuable target for applied
research (Vogelstein et al., 2013). Therefore, much research has gone into both
therapeutic strategies to restore mutant to wild-type p53 and pretreatment of cancer
cells with p53 activators that arrest noncancerous p53-normal proliferating cells without
impacting the cell cycle of cells with a p53 mutation, thus allowing for selective killing
of cancerous cells.
Current research on this type of treatment has led to the discovery of small molecules
that directly or indirectly activate p53. Some p53 activation has been achieved in the
clinic. The most advanced of these are the p53 mdm2 interaction inhibitors. The first
class of small molecule mdm2 inhibitors discovered was nutlin-3a, which binds to the
hydrophobic cleft in the N-terminus of mdm2, preventing its association with p53 and
initiating the cascade. Since this discovery of nutlin-3a, many more related compounds
Published by Digital Commons @ Olivet, 2019
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have been tested, some of which have now made it to the preclinical stage. This stage
will better assess the biological effects and toxicity of the treatment to patients (Burgess
et al., 2016). As research continues and understanding of p53 response increases,
development will continue allowing for powerful drug combinations that may increase
the selectivity and safety of chemotherapy by selective protection of normal cells and
tissue (Lane et al., 2010).
Alpha mangostin as a chemoprotectant
Alpha mangostin is a p53 activator that is isolated from the carp of the Garcinia
mangostana (Mangosteen fruit), which is native to Thailand and traditionally used for
antioxidant, antitumoral, antiallergic, anti-inflammatory, antibacterial, and antiviral
medicinal purposes (Pedraza-Chaverri, Cárdenas-Rodríguez, Orozco-Ibarra, & PérezRojas, 2008). This extract is known to inhibit the binding of p53 to MDM2, a negative
regulator of p53.
In one study in 2011, alpha mangostin was used to reduce tumor growth and lymph
node metastasis in an immunocompetent xenograft model of metastatic mammary
cancer with a p53 mutation. The study showed that treatment with 20 mg/kg/day
alpha mangostin resulted in prolonged survival rates and increased inhibition of tumor
growth and lymph node metastasis (Shibata et al., 2011). This reveals that this extract
at high concentrations can potentially be a successful treatment for p53 mutated cancer
types. Meanwhile, at lower concentrations, alpha mangostin has the potential to act as
a chemoprotectant to wild-type cells. One study tested the chemoprotection of alpha
mangostin on wild-type BHK cells. The results supported the hypothesis that alpha
mangostin can be used to protect cells from the cytotoxic effects of chemotherapy
(Wojciechowski, 2017). However, the effect on breast cancer cell lines at low
concentrations is not known. Here, this research seeks to determine whether or not
the alpha mangostin pretreatment would be an effective strategy for chemoprotection
of wild-type cells by testing whether or not the cancer cells are also protected. If
the data indicate that the cancerous cells are not protected, this p53 activator could
potentially be a successful pretreatment before chemotherapy for selective cancer
killing. I hypothesize that alpha mangostin, a p53-dependent chemoprotectant, protects
wild-type cells but not those with a p53 mutation from the chemotherapeutic agent
paclitaxel.
MATERIALS AND METHODS
Culturing of MCF10A cells
Cell culture protocol was based on the ATCC© Thawing, Propagating, and
Cryopreserving Protocol (“Thawing, Propagating, and Cryopreserving Protocol:
MCF10A-JSB Breast epithelium,” 2012). MCF10A p53 Wild-type and p53 knockout
(-/-) human breast cancer cells were cultured in Dulbecco’s Modified Eagle’s Medium
supplemented with cholera toxin from V. cholera, insulin solution, epidermal growth
factor, 50 uM hydrocortisone solution, and horse serum at 37°C. PBS was used to rinse
the wells before lifting. Trypsin-EDTA solution was used to lift cells.

258https://digitalcommons.olivet.edu/elaia/vol2/iss1/16

6

Van Oost: Study of Alpha Mangostin as a Chemoprotective Agent for Breast Ca

Determining the toxicity of alpha mangostin and paclitaxel
Cells were treated at various levels of alpha mangostin and paclitaxel to create a dose
response curve and toxicity curve and determine workable concentrations for the
dual treatment experiments. For the dual treatment, cells were treated with various
concentrations of alpha mangostin, ranging from 0 to 0.25 uM, for twenty-four hours
followed by a twenty-four-hour dual treatment of alpha mangostin and 15 nM paclitaxel.
Differentiating between viable, apoptotic, and necrotic cells
Cells were stained with Hoechst, YO-PRO 1, and propidium iodide to differentiate
between viable, apoptotic, and necrotic cells. Data was collected on cell viability
using differential fluorescent staining. The differences were shown through fluorescent
microscopy with Hoechst, propidium iodide, and YO-PRO-1 stains. The Hoechst stain
only stains normal healthy cells. The next two, propidium iodide and YO-PRO-1, only
stains necrotic and apoptotic cells, respectively. Through these three stains, I will be
able to only evaluate the attached cells for comparison. Quantitatively, the cells stained
with Hoechst stain were used for the results section. However, the two other stains are
shown in the figures with photos. Representative pictures at 10x were taken blindly by
a professor in order to eliminate bias and counted using the fluorescent cell counting
program.
Development and use of cell counting program
The program used to count the cells was developed by Evan Dexter using Microsoft
Visual Studio in C# language. The code for this program is shown in Appendix 1. It
works by use of an algorithm that examines the color values of the picture’s pixels.
Pixels with high values of the color being counted are flagged as potential cell locations.
Various user-controlled parameters are then used to refine the number of cells from the
initial list. Changing the parameters makes it possible to count the number of cells for
different types of cells and conditions. The resulting count is displayed to the user as
both a sum total and a marker on each cell location (Dexter 2019).
RESULTS
Data shown in the results section come from representative photos taken at 100x on
a fluorescent microscope and analyzed using a double-blind method. Typical methods
such as the cell hemocytometer were not able to be used due to difficulties lifting
the cells without killing them. Therefore, a program was developed that would
count representative photos to have an idea of cell viability in each of the treatment
wells (Appendix 1). Viable cells were counted as indicated by the blue Hoechst
stain. Concentration ranges for toxicity curves and dose response curves were
based upon previous research using these treatments with baby hamster kidney cells
(Wojciechowski, 2017).
Single treatment results for wild-type cells (p53 pathway intact)
We first wanted to determine the effect of the chemotherapeutic drug, paclitaxel,
on the MCF10A wildtype cells. This procedure allowed for the determination of a
concentration that would be suitable for dual treatment with alpha mangostin.
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Figure 3. Fluorescent microscopy of MCF10A wild-type
cells after treatment with
paclitaxel. A is the control, B is
10 nM, C is 25 nM, and D is 35
nM. Increase in concentration
led to a decrease in live cell
count.

Increasing concentrations of alpha mangostin caused a decrease in the number of cells
in the well (Figures 3 and 4). There were not many floating dead cells in the wells,
which indicate that the decrease in cell number was likely due to cell cycle arrest.
The control well had a variable number of cells in each well, as indicated by the large
error bars in Figure 4. If experimental error did not have an effect on the results of
the control well then very low concentrations of paclitaxel had a mitogenic effect on
the wild-type MCF10A cell line. The chosen concentration of paclitaxel for the dual
treatment was 15 Nm, as higher concentration did not give a sufficient number of cells
to allow for variable cell counts with lower standard error.
Figure 4. Wild-type MCF10A
paclitaxel toxicity curve.
Cells were treated with
concentrations ranging from
0-35 nM for twenty-four
hours, and the cell count per
field of view was recorded per
well. The 5, 10, and 15 nM
concentration of paclitaxel
had a mitogenic effect on the
cells with toxicity beginning
at 25 nM.
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We next sought to determine the effect of alpha mangostin on cell viability for the
wild-type MCF10A cells. This experiment was also done in order to determine an
acceptable range for the dual treatment for this cell line with the chemotherapeutic
agent, paclitaxel.
Figure 5. Fluorescent
microscopy of MCF10A
wild-type cells after
treatment with alpha
mangostin. Top left is the
control, top right is 0.05 μM,
bottom left is 0.15 μM, bottom
right is 0.25 μM. Increase in
concentration led to a decrease
in live cell count

The MCF10A wild-type cells responded in a dose dependent manner (Figure
5 and 6). In addition to the control, varying concentrations ranging from 0.05
to 0.25 were used because it gave a suitable range that had variable cell counts.
Figure 6. Wild-type
MCF10A alpha mangostin
dose response curve. Cells
were treated with varying
concentrations of alpha
mangostin for twenty-four
hours and counted using the
fluorescent cell counting
program.
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Dual treatment results for wild-type cells (p53 pathway intact)
The final experiment for the wild-type cells was the dual treatment with alpha
mangostin for twenty-four hours followed by a combination of alpha mangostin
and paclitaxel for another twenty-four hours.

Figure 7. Wild-type MCF10A alpha mangostin and paclitaxel dual treatment. Cells were treated with varying
concentrations of alpha mangostin for 24 hours and counted using the fluorescent cell counting program.

Cells treated with alpha mangostin alone and those cotreated with paclitaxel
yielded similar cell counts (Figure 7). While these results indicate a negligible
effect of alpha mangostin as a chemoprotectant, we also observed a wide variety
of experimental error as will be discussed further below.

Figure 8. Fluorescent microscopy of wild-type MCF10A paclitaxel treatment vs dual treatment with alpha
mangostin. Left is the paclitaxel only treatment and right is the alpha mangostin paclitaxel dual treatment.

262https://digitalcommons.olivet.edu/elaia/vol2/iss1/16

10

Van Oost: Study of Alpha Mangostin as a Chemoprotective Agent for Breast Ca

Single treatment results for MCF10A p53 (-/-) cells
P53 is known to be an important regulator of cell cycle arrest and as noted
above is often absent in numerous cancers. We therefore wanted to determine
the role of a chemoprotectant such as alpha mangostin on p53 knockout cells
(Figures 9 and 10). The concentration range used was slightly larger than that
used for the wild-type cells to gain a better understanding of the effect of the
concentration on the treatment.

Figure 9. Fluorescent microscopy of MCF10A p53 (-/-) cells after treatment with alpha mangostin. Top left
is the control, top right is 0.1 μM, bottom left is 0.5 μM, bottom right is 1 μM. Dark grey cells indicate live cells
stained with Hoechst, and light grey cells indicate apoptotic cells, and black cells indicate necrotic cells. Increasing
concentrations led to a decrease in live cell count.

In addition to quantitative data, the wells were qualitatively assessed through a
blinded observation to determine the approximate cell viability (Figure 11). It
was important to perform this study for this experiment because the obtained
counts for Figures 9 and 10 were not particularly representative. This is
because photos were taken at the edges of the wells since the middle of the well
had limited consistency in all treatments. Viability was greatly diminished at
concentration of 0.25 or greater, which is in contrast to what was observed with
MCF10A wild-type cells.
Published by Digital Commons @ Olivet, 2019
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Figure 10. MCF10A p53 (-/-) alpha mangostin dose response curve. Cells were treated with varying
concentrations of alpha mangostin for twenty-four hours and counted using the fluorescent cell counting program.

Figure 11. Qualitative observation of percent viability for increasing treatments of alpha mangostin on
MCF10A p53 (-/-) cells. Observations of this percentage were estimated using a blind study method.
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DISCUSSION
Through induction of p53-dependent G2 arrest, pretreatment can prevent cell death
caused by microtubule-inhibiting drugs such as paclitaxel. This would allow for
selective killing of p53 mutant cancer cells (Blagosklonny, 2002). In order to assess
the chemoprotective abilities of alpha mangostin, we performed several experiments
on MCF10A wildtype and p53 (-/-) breast cancer cells. When working with this cell
line, a lot of troubleshooting and method alterations went into the process of creating
the experiments. This is important to note because the major time commitment for this
troubleshooting did not allow for duplication of the experiments. In order to fully draw
conclusions from this research, one must duplicate the data in order to gain confidence
in the results presented. Also, it is important to note that the key findings presented in
Figure 11 came from a double blinded study to avoid bias.
To begin, the MCF10A wildtype cells were treated with both alpha mangostin and
paclitaxel separately to create a toxicity and dose response curve in order to determine
a workable range of concentrations for alpha mangostin and an optimum concentration
of paclitaxel for the dual treatment. As shown in Figure 4, a 15 nM concentration of
paclitaxel had higher confidence, shown by smaller error bars, and had a significant
fraction of less cells than the 5 nM treatment. The mitogenic effect of lower doses in
contrast to the low number of cells in the control well may be a result of experimental
error. This concentration has the potential to give room for variation of cell number
when pretreated with alpha mangostin. Thus, the 15 nM concentration was chosen to
be the fixed paclitaxel concentration for the dual treatment.
Figure 6 shows that alpha mangostin responds in a dose dependent manner. These
concentrations were shown to be effective to be used for the dual treatments. Therefore,
the next experiment included a dual treatment in which cells were treated with
concentrations of 0.00 μM to 0.25 μM of alpha mangostin on day 1 and treated with
both alpha mangostin and 15 nM paclitaxel on day 2 (Figure 7). The results of this
dual treatment show similar cell counts for cultures treated with and without paclitaxel,
indicating that alpha mangostin is able to effectively protect cells from the normally
cytotoxic effects of paclitaxel. This conclusion is based on the paclitaxel toxicity curve
that shows that adding each subsequent concentration of paclitaxel should decrease
cell number. However, the cells treated with alpha mangostin and no paclitaxel and
the cells that were dual treated had very similar values. Overall, the wells that were
pretreated with alpha mangostin had a much larger live cell count than the well that
received no alpha mangostin pretreatment before it was treated with paclitaxel (Figure
8). Because the wild-type cells are also representative of typical human breast cells
with wild-type p53, these experiments indicate that human breast cells will be protected
from paclitaxel by alpha mangostin.
The second section of results evaluates the effect of pretreatment of p53 knockout
MCF10A cells to ensure that these cells are not protected by the alpha mangostin. If
the alpha mangostin showed a similar protective effect, then it would not be a useful
selective treatment for breast cancer. To explore the relationship between the knockout
cells and the alpha mangostin, a dose response treatment, ranging from 0 to 1 μM alpha
Published by Digital Commons @ Olivet, 2019
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mangostin, was administered to knockout cells for twenty-four hours (Figure 10).
Based on the mechanism of p53 activators, which includes inhibition of mdm2-p53
interaction in the normal pathway, cell count numbers were expected to be consistent
in different concentrations of alpha mangostin. However, number of cells decreased
with increasing alpha mangostin concentration. Further analysis revealed that the wells
with higher concentrations of alpha mangostin had many dead cells that were floating
and thus not recognized by the fluorescent microscope. These dead cells indicate that
the low number of cells at high concentrations is not due to cell arrest, but rather from
cell toxicity. The decrease in cell number is shown in Figures 9, 10 and 11. Figure 10
contains quantitative data that shows a relative decrease in cell number correlates to
an increase in concentration. Figure 11 contains a qualitative observation of percent
viability for increasing treatments of alpha mangostin on MCF10A p53 (-/-) cells. The
percent confluence decreased as alpha mangostin increased. Overall, these data show
that the number of cells depends on the concentration of the alpha mangostin in a dose
dependent manner.
Overall, the range of concentration of alpha mangostin between 0.1 μM to 0.25 μM
showed a protective benefit to wild-type MCF10A breast cancer cells. Furthermore, the
same concentration range decreased cell viability of the MCF10A p53 knockout cell line.
This indicates that alpha mangostin has potential as a selective cancer treatment when
paired with the chemotherapeutic drug paclitaxel. While these results are encouraging
and suggest that alpha mangostin is a potential chemoprotectant for chemotherapy, it
is important to acknowledge the limitations of this research. Due to difficulties and
troubleshooting, only one trial for each of these various treatments was completed.
Therefore, in order to fully validate this research, it must be replicated to eliminate any
results which came from experimental error. Along with replication of this experiment,
it would be beneficial to continue the knockout MCF10A p53 (-/-) study and perform a
toxicity curve with paclitaxel in order to perform a dual treatment study. Furthermore,
these experiments should be performed on several different cell lines to evaluate the
effectiveness of alpha mangostin on different cell types and cancers. Further research
is required to explore the promising pretreatment to chemotherapy, alpha mangostin.
Although many treatments exist for cancer, scientists are always looking for better and
more effective options for patients. When evaluating treatment plans, patients must
consider both the effectiveness of the treatment and the negative side effects of each
treatment option. While chemotherapy has shown to be an effective and aggressive
treatment option, it is not selective for that tissue, and therefore has many harsh
side effects including pain, lymphedema, musculoskeletal symptoms, bone loss and
osteoporosis, heart problems, new cancer development, blood clots, infertility, and loss
of memory and cognitive function (American Cancer Society, 2017). This research,
as well as other studies, show that alpha mangostin has potential as a p53 activation
pretreatment before chemotherapy to limit these side effects.
The p53 gene is a great potential target for cancer treatment because it is the most
frequently altered gene in human cancers (Shibata et al., 2011). If alpha mangostin
can be used as a tool for chemoprotection in a p53-dependent manner in breast cancer
development, then it would enable doctors to treat patients with higher concentrations
266https://digitalcommons.olivet.edu/elaia/vol2/iss1/16
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of chemotherapy without harming healthy tissue. It would also potentially have
implications in treatments of other types of cancer, such as some uterine, ovarian, and
lung cancers, which also have a high prevalence of p53 mutations. Alpha mangostin
offers a more natural treatment option that can be easily translated to clinical use
because it is already FDA approved. Overall, this study shows that alpha mangostin
warrants further research to better understand its effectiveness as a pretreatment for
chemotherapy.
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APPENDIX 1
Please see the complete version of this paper on Olivet Nazarene University’s Digital
Commons for the fluorescent cell counting software code.
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